SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
apt12091-sup-0001-FigS1.tifimage/tif920KFigure S1. ROC curves of CK-18 M30, M65 and M65ED in predicting NAFLD, NASH and NAS ≥5. ROC curves in (a) distinguishing NAFLD patients from control subjects, (b) distinguishing NASH from non-NASH NAFLD patients and (c) distinguishing NAFLD patients with NAS ≥5.
apt12091-sup-0002-FigS2.tifimage/tif902KFigure S2. Serum level of CK-18 M30, M65 and M65ED with different histological features in NAFLD patients. Comparison among different (a) steatosis, (b) lobular inflammation, (c) ballooning and (d) fibrosis grades. *Significant at P < 0.05; **Significant at P < 0.01; N.S., not statistically significant.
apt12091-sup-0003-FigS3.tifimage/tif196KFigure S3. Serum level of CK-18 M30, M65 and M65ED in NAFLD patients according to NAS subgroups. M30 in NAS subgroups: (1–2): 265 (180–418) U/L; (3–4): 366 (223–548) U/L; (5–8): 476 (326–988) U/L; M65 in NAS subgroups: (1–2): 534 (411–795) U/L; (3–4): 765 (572–1038) U/L; (5–8): 954 (759–1762) U/L; M65ED in NAS subgroups: (1–2): 196 (135–374) U/L; (3–4): 466 (253–802) U/L; (5–8): 740 (449–1264) U/L. *Significant at < 0.05; **Significant at < 0.01; N.S., not statistically significant.
apt12091-sup-0004-FigS4.tifimage/tif688KFigure S4. Changes of serum level of CK-18 M30, M65 and M65ED and disease progression in 51 patients received paired live biopsies. Comparison between patients with or without (a) NAFLD activity score worsened, (b) disease progression from non-NASH to NASH (15 patients who were diagnosed as NASH at both time points were excluded) and (c) fibrosis progression. *Significant at < 0.05; **Significant at < 0.01; N.S., not statistically significant.
apt12091-sup-0005-FigS5.tifimage/tif901KFigure S5. ROC curves changes of CK-18 M30, M65 and M65ED in predicting disease progression. ROC curves in (a) distinguishing patients with NAFLD activity score worsened, (b) distinguishing patients with disease progression from non-NASH to NASH and (c) distinguishing NAFLD patients with fibrosis progression.
apt12091-sup-0006-TableS1-S3.docxWord document17K

Table S1. Clinical characteristics of NAFLD patients’ population according to NAS.

Table S2. Accuracy of biomarkers.

Table S3. Correlations between change of biomarkers and disease progression in 51 patients with paired liver biopsy.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.